EGF-modified mPEG-PLGA-PLL nanoparticle for delivering doxorubicin combined with Bcl-2 siRNA as a potential treatment strategy for lung cancer.
CONCLUSION: We conclude that co-delivery of Dox and Bcl-2-siRNA by tumor-targeted EGF-PEAL NPs could significantly inhibit lung cancer growth.
PMID: 26739487 [PubMed - as supplied by publisher]
Source: Drug Delivery - Category: Drugs & Pharmacology Tags: Drug Deliv Source Type: research
More News: Cancer | Cancer & Oncology | Drugs & Pharmacology | Lung Cancer | Nanotechnology | Polyethylene Glycol